Fibrogen receives complete response letter from the fda for roxadustat for anemia of chronic kidney disease

San francisco, aug. 11, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced that the u.s. food and drug administration (fda) has issued a complete response letter regarding the new drug application (nda) for roxadustat for the treatment of anemia of chronic kidney disease (ckd).

FGEN Ratings Summary

FGEN Quant Ranking